Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
Rigel Medical
Primedic

Zoll Acquires Intellectual Assets of Coaxia

By HospiMedica International staff writers
Posted on 15 Jul 2013
ZOLL (Chelmsford, MA, USA) has purchased the assets of CoAxia (Maple Grove, MN, USA), an early revenue stage medical device company that provides catheter-based perfusion augmentation therapies.

The core application ofCoAxia’s catheter technology, distributed under the trade names NeuroFlo and FloControl, involves the redistribution of blood flow from the lower extremities to support brain function during cerebral ischemia resulting from vasospasm, following subarachnoid hemorrhage. CoAxia did not have the funds to continue development after its de novo petition for the NeuroFlo catheter was rejected by the US Food and Drug Administration (FDA) for acute ischemic stroke. Zoll, however, still sees opportunity for the device and plans to design a new pivotal trial to take before the FDA.

Both NeuroFlo and FloControl blood flow redistribution technology use dual balloons to create temporary partial obstruction in the descending aorta. This technique causes a redistribution of cardiac output from the lower extremities to the cerebral vasculature without significantly increasing arterial blood pressure. The acquisition of the intellectual property also includes several key patents on cerebral perfusion augmentation as well as numerous other patents relevant to other various vascular procedures. Financial terms of the purchase were not disclosed.

“NeuroFlo technology has the potential to address a large portion of the population who suffer cerebral ischemia, offering a significant benefit to patients and the healthcare system,” said James Palazzolo, president of Zoll. “Our task is to continue to develop the significant body of clinical evidence started by CoAxia demonstrating the safety and efficacy of the NeuroFlo catheter and, in the end, do what is necessary for it to be a standard treatment option for hundreds of thousands of stroke patients worldwide.”

The acquisition of CoAxia’s intellectual property also offers synergy with Zoll’s acute critical care portfolio of products such as temperature management, which may reduce reperfusion injury following ischemia by using balloon catheters. The devices could also offer significant potential applications in blood flow redistribution for trauma, cardiac arrest, coronary procedures, surgical blood loss, and renal perfusion.

Related Links:

ZOLL
CoAxia



Channels

Critical Care

view channel
Image: The Connex Spot Monitor (Photo courtesy of Welch Allyn).

Wireless Vital Signs Monitor Improves Patient Safety

A new clinical patient monitor automates collection of vital signs, sharing the data automatically with hospital and physician electronic medical record (EMR) systems. The Connex Spot Monitor is a... Read more

Women's Health

view channel

Tampons Could Help Predict Endometrial Cancer

A new study shows that vaginal secretions in tampons can be used to detect the presence of endometrial cancer DNA. Researchers at the Mayo Clinic (Rochester, MN, USA) obtained samples from 66 women who were about to undergo a hysterectomy, 38 of them due to endometrial cancer and 28 due to other indications.... Read more

Hospital News

view channel

Ventas to Buy Healthcare Services Provider Ardent

Healthcare real-estate investment trust (REIT) Ventas (Chicago, IL, USA) will buy hospital operator Ardent Medical Services (Nashville, TN, USA) for USD 1.75 billion in cash. Under the terms of the agreement, Ventas will own 10 hospital properties and will separate their operations into entities that will be owned by... Read more
 

Events

21 Apr 2015 - 24 Apr 2015
27 Apr 2015 - 29 Apr 2015
28 Apr 2015 - 01 May 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.